[New drug arrival : Pembrolizumab as second-line treatment in MSI-H/dMMR endometrial, colorectal, gastric, intestinal and biliary cancers]

Nathan El-Ghazzi; Benoit Rousseau; Manuel Rodrigues

doi:10.1016/j.bulcan.2022.10.003

[New drug arrival : Pembrolizumab as second-line treatment in MSI-H/dMMR endometrial, colorectal, gastric, intestinal and biliary cancers]

Bull Cancer. 2023 Jan;110(1):11-13. doi: 10.1016/j.bulcan.2022.10.003. Epub 2022 Nov 7.

[Article in French]

Authors

Nathan El-Ghazzi¹, Benoit Rousseau², Manuel Rodrigues³

Affiliations

¹ Service d'oncologie médicale, CHU Clermont-Ferrand, Clermont-Ferrand, France. Electronic address: [email protected].
² Memorial Sloan Kettering Cancer Center, New York, NY, États-Unis.
³ Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), équipe labellisée par la ligue nationale contre le cancer, Paris, France; Institut curie, département d'oncologie médicale, PSL research university, 26, rue d'Ulm, 75005 Paris, France.

PMID: 36357200
DOI: 10.1016/j.bulcan.2022.10.003

No abstract available

Keywords: Biliary cancer; Cancer biliaire; Cancer colorectal; Cancer de l’endomètre; Cancer gastrique; Colorectal cancer; Endometrial cancer; Gastric cancer; Immunotherapy; Immunothérapie; Mismatch repair deficiency; Système du mismatch repair.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Biliary Tract Neoplasms*
Brain Neoplasms
Colorectal Neoplasms* / drug therapy
DNA Mismatch Repair
Humans
Microsatellite Instability
Neoplastic Syndromes, Hereditary

Substances

pembrolizumab
Antibodies, Monoclonal, Humanized

Supplementary concepts

Turcot syndrome